JONATHAN FAWCETT, M.B.B.S., D.Phil.

Vice President, Head of Clinical Development

Jonathan Fawcett, MBBS DPhil., Vice President, Head of Clinical Development of Sutro since March 2025. He joined Sutro in September, 2024, bringing more than 20 years of experience across drug development in both pharmaceutical and clinical research settings.

Prior to joining Sutro, he served as Executive Medical Director, Clinical Development at Exelixis, where he led a Phase 3 study in first-line advanced hepatocellular carcinoma before transitioning to early-stage clinical development. In that role, he worked on antibody-drug conjugate and immuno-oncology assets from IND preparation through early-phase clinical studies, including two Tissue Factor-targeted ADCs.

Before joining industry, Jonathan led a large clinical team in liver transplantation and surgery in Australia and was also an active member of the Australasian GI Trials Group. His clinical research focused on donor organ preservation and primary and metastatic hepatobiliary malignancies.

Jonathan holds an M.B.B.S. with First Class Honours in Medicine from the University of Newcastle upon Tyne, and a D.Phil. in Molecular Biology from the University of Oxford, where his graduate research at the Institute of Molecular Medicine focused on cell adhesion molecules and recombinant protein synthesis.